Sameer Savkur, country manager of Biogen Brazil, provides insights into the key specificities of the Brazilian pharmaceutical ecosystem and documents the great successes of Biogen affiliate in working hand-in-hand with all key public and regulatory stakeholders in Brazil, as recently illustrated with Biogen’s innovative treatment for spinal muscular atrophy (SMA), a groundbreaking product which received all regulatory and pricing approvals in a record time.
You headed Biogen’s affiliate in India between 2011 and 2014 before taking over the company’s Brazilian operations in February 2015. Which similarities between the two countries have facilitated your transition from India to Brazil?
"I personally believe that the first and foremost mission of any general manager is to build and enhance enriching work relationships – both at the internal and external levels."
